AKAP4 is an inclusion criterion in 2 clinical trials for chronic lymphocytic leukemia, of which 0 are open and 2 are closed. Of the trials that contain AKAP4 status and chronic lymphocytic leukemia as inclusion criteria, 2 are phase 1/phase 2 (0 open) [4].

AKAP4 is an inclusion criterion in 2 clinical trials for hodgkin lymphoma, of which 0 are open and 2 are closed. Of the trials that contain AKAP4 status and hodgkin lymphoma as inclusion criteria, 2 are phase 1/phase 2 (0 open) [4].

AKAP4 is altered in 0.01% of malignant solid tumor patients [3].

AKAP4 is an inclusion criterion in 2 clinical trials for malignant solid tumor, of which 0 are open and 2 are closed. Of the trials that contain AKAP4 status and malignant solid tumor as inclusion criteria, 2 are phase 1/phase 2 (0 open) [4].

AKAP4 is an inclusion criterion in 2 clinical trials for multiple myeloma, of which 0 are open and 2 are closed. Of the trials that contain AKAP4 status and multiple myeloma as inclusion criteria, 2 are phase 1/phase 2 (0 open) [4].

AKAP4 is an inclusion criterion in 2 clinical trials for non-hodgkin lymphoma, of which 0 are open and 2 are closed. Of the trials that contain AKAP4 status and non-hodgkin lymphoma as inclusion criteria, 2 are phase 1/phase 2 (0 open) [4].

AKAP4 is an inclusion criterion in 1 clinical trial for acute lymphoblastic leukemia, of which 0 are open and 1 is closed. Of the trial that contains AKAP4 status and acute lymphoblastic leukemia as inclusion criteria, 1 is phase 1/phase 2 (0 open) [4].

AKAP4 is an inclusion criterion in 1 clinical trial for acute myeloid leukemia, of which 0 are open and 1 is closed. Of the trial that contains AKAP4 status and acute myeloid leukemia as inclusion criteria, 1 is phase 1/phase 2 (0 open) [4].

AKAP4 is an inclusion criterion in 1 clinical trial for chronic myeloid leukemia, of which 0 are open and 1 is closed. Of the trial that contains AKAP4 status and chronic myeloid leukemia as inclusion criteria, 1 is phase 1/phase 2 (0 open) [4].